Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLX10010 in Healthy Subjects for Hypertrophic Scars
NCT03569267Phase 1Completed
- Sponsor
- OliX Pharmaceuticals
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Hypertrophic Scar (HS) comparing OLX10010 Arm with Placebo Arm (2 arms). Primary endpoint: Number of subjects with treatment-related adverse events as assessed by CTCAE v4.0 at 14 days. Started May 2018; status: completed.
02
Drugs
OLX10010
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT03569267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569267.